Evidence map›Paper›PMID 34085034›Full record

ArticleACS applied bio materials2021

Antibody-Functionalized Halloysite Nanotubes for Targeting Bacterial Cells.

Ofer Prinz Setter, Ariel Movsowitz, Sarah Goldberg, Ester Segal

Abstract read
In one paragraph

Article in ACS applied bio materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Biotransformation of (-)-Isopulegol byPharmaceuticals (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ofer Prinz SetterDepartment of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Technion City, Haifa 3200003, Israel.
Ariel MovsowitzDepartment of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Technion City, Haifa 3200003, Israel.
Sarah GoldbergDepartment of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Technion City, Haifa 3200003, Israel.
Ester SegalDepartment of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Technion City, Haifa 3200003, Israel.ORCID 0000-0001-9472-754X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Halloysite nanotubes (HNTs) are naturally occurring tubular clay particles which have emerged in recent years as a promising nanomaterial for numerous applications. Specifically, HNTs' large pore volume and high specific surface area in combination with their biocompatibility make them ideal nanocarriers for bioactive compounds. This research aims to design and synthesize functionalized HNTs, which could selectively bind to target bacterial cells in suspension. Such a system can allow us to treat target cells within a challenging heterogeneous population, such as contaminated ecosystems or gut flora. HNTs functionalization is achieved by immobilizing specific antibodies onto the nanotube surface. The synthetic route is realized by the following subsequent steps: acidic etching of the HNTs, silanization of reactive surface hydroxyls, conjugation of protein A, and oriented immobilization of the antibody. HNT functionalization is studied by a set of analytical techniques including attenuated total reflectance Fourier-transform infrared spectroscopy, zeta potential measurements, thermal gravimetric analysis, scanning and transmission electron microscopy, as well as fluorescence microscopy. The selective binding of the functionalized HNTs to their target bacteria is observed upon incubation with live homogenous and heterogeneous cultures using fluorescence microscopy and high-throughput flow cytometry. Plate count and live/dead staining experiments demonstrate the biocompatibility of the antibody-HNT hybrid with its target bacteria. The suggested HNT-based smart carrier constitutes a generic platform for targeted delivery that could be selectively tailored against any microorganism by facile antibody adjustment.

Indexed as

AntibodiesBiocompatible MaterialsEscherichia coliMaterials TestingNanotubesParticle SizeAntibodiesBiocompatible Materials

Identifiers

PMID34085034
PMCPMC8161669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.